The pulmonary arterial hypertension market has experienced significant growth in recent years, and this trend is projected to persist. The market that was valued at $8.47 billion in 2024 is forecasted to reach $9.24 billion in 2025, growing at a compound annual growth rate (CAGR) of 9.1%. Factors such as increased awareness of pulmonary arterial hypertension (PAH), rise in healthcare expenditure, growth in the aging population, and expansion of PAH treatment options have been instrumental in advancing the historic period. Furthermore, as investment in research and development activities for pulmonary hypertension intensifies, the market is poised for even more rapid growth. The pulmonary arterial hypertension market size is predicted to soar to $12.97 billion in 2029 at a CAGR of 8.8%.
Get Your Free Sample of The Global Pulmonary Arterial Hypertension Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=5954&type=smp
What Key Segments Influence the Dynamics of the Pulmonary Arterial Hypertension Market?
1) By Drug Class: Endothelin Receptor Antagonists (ERAs), PDE-5 Inhibitors, Prostacyclin and Prostacyclin Analogs, SGC Stimulators
2) By Route Of Administration: Oral, Intravenous Or subcutaneous, Inhalational
3) By Distribution channel: Retail, Online
Expect Immediate Delivery of the Pulmonary Arterial Hypertension Market Report:
https://www.thebusinessresearchcompany.com/report/pulmonary-arterial-hypertension-global-market-report
Which Major Players Are Operating in the Pulmonary Arterial Hypertension Market?
The pulmonary arterial hypertension market is populated by several key players, including United Therapeutics Corporation, Acceleron Pharma Inc., Actelion Pharmaceuticals US Inc., Bayer AG, Eli Lilly and Company, Gilead Sciences Inc., GlaxoSmithKline plc, Johnson & Johnson, Liquidia Technologies Inc., Lupin Pharmaceuticals Inc., Natco Pharma Ltd., Pfizer Inc., Sandoz AG, Teva Pharmaceutical Industries Ltd., Zydus Pharmaceutical USA Inc., and more.
Which Emerging Trends Are Influencing the Pulmonary Arterial Hypertension Market?
Major companies in the pulmonary arterial hypertension market have been developing advanced products to enhance treatment outcomes for patients battling this severe condition. For instance, in March 2024, U.S.-based multinational pharmaceutical company Merck & Co., Inc. introduced Winrevair, a groundbreaking treatment for adults with pulmonary arterial hypertension (PAH). Winrevair is the first-ever therapy approved by the FDA, a US-based federal agency, that targets activin signaling for PAH. This novel treatment seeks to restore balance between pro- and anti-proliferative signals that regulate the vascular cell proliferation associated with PAH, thereby presenting a new class of therapy for the condition.
Which Region Dominates the Pulmonary Arterial Hypertension Market?
As of 2024, North America was the largest region in the Pulmonary Arterial Hypertension Market, trailed by Asia-Pacific, Western Europe, Eastern Europe, South America, Middle East, and Africa.
What Does The Pulmonary Arterial Hypertension Market Report 2025 Offer?
Pulmonary arterial hypertension is essentially a chronic and incurable excessive blood pressure condition that compromises the right side of the heart and the lungs’ arteries. This causes the artery walls in the lungs to become contracted and stiff. The Pulmonary Arterial Hypertension Market research report from The Business Research Company offers crucial insights into global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities. The report elucidates how PAH drugs work to relax the muscles in the walls of the blood vessels, enhance the blood flow through the lungs, or counteract the effect of the substance in the walls of blood vessels that narrows them.
Unlock Exclusive Market Insights by Purchasing the Report:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=5954
About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has established a reputation for providing extensive, data-rich research and insights. With the aid of 1,500,000, our datasets, the valuable contribution from in-depth secondary research, and unique insights from industry leaders, you have all the information you need to stay ahead. Our flagship product, the Global Market Model, is an exemplary market intelligence platform delivering comprehensive and updated forecasts to facilitate informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
